ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Impact of a De Novo Belatacept Based Immunosuppressive Regimen on Kidney Transplant Outcomes

K. Joyal, T. Vanhove, B. Schreiber, M. Cote, S. Shao, N. Elias, H. Gilligan, K. Safa, E. Heher, W. Williams, C. Rogers

Massachusetts General Hospital Transplant Center, Boston, MA

Meeting: 2020 American Transplant Congress

Abstract number: C-113

Keywords: Immunosuppression, Kidney, Rejection

Session Information

Session Name: Poster Session C: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Use of anti-thymocyte globulin (rabbit) (rATG) induction with belatacept/mycophenolate (MPA)/prednisone based immunosuppression (IS) has led to a reduction in rejection compared to that seen with basiliximab. This study sought to determine if use of belatacept with maintenance everolimus and prednisone would improve efficacy and maintain safety.

*Methods: Retrospective, single-center analysis of 33 EBV seropositive kidney transplant recipients (KTRs) with at least 6 months of follow up (f/u). KTRs received 4.5 mg/kg rATG or basiliximab induction, FDA approved dosing of belatacept, and MPA or everolimus with prednisone.

*Results: Clinical characteristics and details of rejection treatment and management are presented in Table 1 and Table 2. All patients were alive at month 6 and at the end of study follow up (67% with 12 month f/u). One patient experienced graft loss on POD 78. Median eGFR in those with functioning grafts w/o rejection was 62 and with rejection was 61.4. Ten patients developed a viral infection (CMV, BKV, Influenza, HSV) and 8 developed a bacterial infection. One patient developed squamous cell carcinoma.

*Conclusions: A de novo belatacept based regimen with rATG induction and maintenance MPA with prednisone resulted in an ACR rate consistent with previous studies which is lower than regimens including basiliximab induction, though still higher than typically seen with tacrolimus-based regimens. As there were only five patients treated with de novo belatacept in combination with everolimus and prednisone, further studies are needed to evaluate the impact of this regimen on safety and outcomes.

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Joyal K, Vanhove T, Schreiber B, Cote M, Shao S, Elias N, Gilligan H, Safa K, Heher E, Williams W, Rogers C. Impact of a De Novo Belatacept Based Immunosuppressive Regimen on Kidney Transplant Outcomes [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-a-de-novo-belatacept-based-immunosuppressive-regimen-on-kidney-transplant-outcomes/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences